Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 180

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 10
Chunk 180
---
 and consent to the Assignment Agreement and agreed to certain amended terms which do not materially differ from the previous license and supply agreement with CH.

94
--
 

Under the terms of the Agreement, CH agreed to make a non-refundable, non-creditable upfront payment to the Company of $1,209 (€1.0 million), which the Company received in January 2021. The Company also is eligible to receive additional consideration, including regulatory milestones related to agreed-upon pricing and reimbursement parameters; net sales milestones; and royalties, ranging from 10%-20% of net sales of macimorelin, subject to reduction in certain cases, or sublicense income recorded by Pharmanovia.
 
As consideration for the right to commercialize the licensed product, Pharmanovia has agreed to pay certain milestones and royalty payments as summarized below:
 
Paediatric Use Regulatory payment (non-refundable and non-creditable)
 

●                                                 Grant                                              
    of first marketing authorization from the European Commission for Paediatric Use of Euro 500,000.
-----------------------------------------------------------------------------------------------------
 
Regulatory payments (non-refundable and non-creditable)
 

●                                                                Upon                                                            
    receipt of pricing and reimbursement approval in France, Germany, Italy, Spain and the United Kingdom upon price per test of:
---------------------------------------------------------------------------------------------------------------------------------
●   Above                                                                                                                        
    Euro 300: Euro 200,000 per country;                                                                                          
●   Euro                                                                                                                         
    250 to Euro 300: Euro 100,000 per country; and                                                                               
●   Achievement                                                                                                                  
    of a mean average reimbursement price of above Euro 300 in France, Germany, Italy, Spain and UK of Euro 500,000.             
 
Commercial milestones (non-refundable and non-creditable)
 

●                                 Annual                              
      net sales reaching Euro 4 million for payment of Euro 250,000;  
----------------------------------------------------------------------
●   Annual                                                            
    net sales reaching Euro 6 million for payment of Euro 400,000;    
●   Annual                                                            
    net sales reaching Euro 8 million for payment of Euro 600,000; and
●   Annual                                                            
    net sales reaching Euro 10 million for payment of Euro 1,000,000. 
Royalties
 

●                            10.0%                          
           for up to Euro 2 million annual net sales;       
------------------------------------------------------------
●                                                      12.5%
        between Euro 2 million and Euro 3 million net sales;
●                                                      15.